Purpose
Our goal was to demonstrate that suitably derivatized monomeric RGD peptide-based PET tracers, targeting integrin αvβ3, may offer advantages in image contrast, time for imaging, and low uptake in non-target tissues.
Methods
Two cyclic RGDfK derivatives, (PEG)2-c(RGDfK) and PEG4-SAA4-c(RGDfK), were constructed and conjugated to NOTA for 64Cu labeling. Their integrin αvβ3-binding properties were determined via a competitive cell binding assay. Mice bearing U87MG tumors were intravenously injected with each of the 64Cu-labelled peptides, and PET scans were acquired during the first 30 min, and 2 and 4 h post-injection (p.i.). Blocking and ex vivo biodistribution studies were carried out to validate the PET data and confirm the specificity of the tracers.
Results
The IC50 values of NOTA-(PEG)2-c(RGDfK) and NOTA-PEG4-SAA4-c(RGDfK) were 444 ± 41, and 288 ± 66 nM, respectively. Dynamic PET data of 64Cu-NOTA-(PEG)2-c(RGDfK) and 64Cu-NOTA-PEG4-SAA4-c(RGDfK) unveiled similar circulation t1/2 and peak tumor uptake of ~4 %ID/g for both tracers. Due to its marked hydrophilicity, 64Cu-NOTA-PEG4-SAA4-c(RGDfK) provided faster clearance from tumor and normal tissues yet maintaining excellent tumor-to-background ratios. Static PET scans at later time-points corroborated the enhanced excretion of the tracer, especially from abdominal organs. Ex vivo biodistribution and receptor blocking studies confirmed the accuracy of the PET data and the integrin αvβ3-specificity of the peptides.
Conclusion
Our two novel RGD-based radiotracers with optimized pharmacokinetic properties allowed a fast, high-contrast PET imaging of tumor associated integrin αvβ3. These tracers may facilitate the imaging of abdominal malignancies, normally precluded by high background uptakes.